NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
Nanjing Leads Biolabs Co.,Ltd
Abramson Cancer Center at Penn Medicine
Scandion Oncology A/S
Incyte Corporation
Merck Sharp & Dohme LLC
University Hospital Tuebingen
EMD Serono
Mirati Therapeutics Inc.
Sanofi